% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • one_dogydog one_dogydog Jan 19, 2013 1:24 PM Flag

    Obesity cost the U.S $300 billion per year and this market is going to ARNA NOT to VVUS!!!!!!!!

    The total economic cost of overweight and obesity in the United States is $270 billion per year while the cost in Canada is about $30 billion a year, a new study shows.
    The $300 billion total cost in the United States and Canada is the result of: increased need for medical care ($127 billion); loss of worker productivity due to higher rates of death ($49 billion); loss of productivity due to disability of active workers ($43 billion); and loss of productivity due to total disability ($72 billion), said the Society of Actuaries (SOA).
    People are considered overweight if their body-mass index (BMI) is between 25 and 29.9 and obese if their BMI is higher than 30.
    When the SOA researchers separated the economic cost of overweight and obesity to the United States in 2009, they found that it was $72 billion for overweight and $198 billion for obesity.
    The findings are based on a review of papers published primarily between January 1980 and June 2009.
    "Overweight and obesity have been shown to increase the rate of several common adverse medical conditions, resulting in this extraordinary economic cost to society," study author Don Behan said in a SOA news release.
    "We can't stand back and ignore the fact that overweight and obesity are drivers of cost increases and detrimental economic effects. It's time for actuaries, the employer community and the insurance industry to take action and help consumers make smart, healthy decisions," he added.

    Arena is now gearing up for what could be the largest launch of the last decade with its weight loss drug Belviq. After months of flat trading, the stock got a lift from its competitor VIVUS, after seeing strong prescription data for VIVUS’ approved weight loss drug. This bodes well for Arena because of its marketing flexibility compared to that of VIVUS. Futhermore, investors are anxiously awaiting a decision from Europe, an approval that could significantly increase its revenue. The stock now looks as though it could trend higher, as investors jump back aboard what could be a fun ride.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.81+0.08(+4.62%)Sep 27 4:00 PMEDT